Ucb Pharma, S.a.

Amgen Inc.

Biogen Idec Ma Inc.

Ucb Biopharma Sprl

Ucb S.a.

Biogen Ma Inc.

Martyn Kim Robinson

John A Latham

Ralph Adams

Kerry Louise Tyson

Ellen A Garber

Andrew George Popplewell

David Guenther Winkler

Yen-Ming Hsu

Linda C Burkly

Hsieng Sen Lu

Frederick Robbins Taylor

Alastair Lawson

Derek Thomas Brown

Lihe Su

Alistair James Henry

Aaron George Winters

Anthony Shock

Janine L Ferrant-Orgettas

Wenyan Shen

Kevin Graham

Christopher J Paszty

Kelly Sue Warmington

Andy Popplewell

Xiaodong Li

David Paul Humphreys

Stephen Edward Rapecki

Andrew Paul Chapman

Mariangela Spitali

Christpher Paszty

Mark Ian Christie

Richard James Mead

Kelly Sue Hoffmann

Hua Zhu Ke

Michael Stuart Ominsky

Kelly Sue Hoffman

The invention relates to the treatment of bone disorders. In particular, the invention is directed to the use of a dosing holiday to help overcome the resistance to anti-sclerostin antibodies which develops over time when a plurality of doses of antibody are given to a subject. By giving the subject to be treated such a dosing holiday, the subject may subsequently display an increased response to a subsequent dose of the anti-sclerostin antibody. The subject may be given multiple cycles of a batch of at least two doses of anti-sclerostin antibody and a dosing holiday. In some instances, the subject may be monitored to help determine when to give the dosing holiday. Further, the subject may be given a different treatment for the bone disorder during the dosing holiday from the anti-sclerostin antibody.

Treatment for bone diseases

The invention relates to the treatment of bone disorders. In particular, the invention provides an approach involving administration of a high initial dose or doses of an sclerostin antibody to bring about a rapid increase in bone formation, followed by administration of lowers doses of the antibody to give a sustained lower rate of bone formation after the initial burst of bone formation. The invention also provides an approach involving decreasing dosing frequency with such an antibody to control bone formation. The approaches may be used in particular in those subjects who would benefit most from such an initial rapid burst of bone formation. Examples of such subjects include subjects who have been recently diagnosed or are experiencing severe symptoms of the disorder, as well as those subjects who have been administered a different treatment for the bone disorder which is proving ineffective. The approaches may be used in combination with each other.

Anti-sclerostin antibodies and their use to treat bone disorders as part of a regimen

This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.

Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereof

Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.

Sclerostin epitopes

The present invention provides a method for the treatment and/or prophylaxis of multiple sclerosis (MS) comprising administering a therapeutically effective amount of an inhibitor of IL-17 activity.

Method for the treatment of multiple sclerosis by inhibiting IL-17 activity

Sclerostin-binding antibodies

The present invention provides anhost cell expressing a recombinant antibody characterized in that thehost cell has been genetically modified in order to change at least one physical property of one or moreproteins which in the wild type copurify with said recombinant antibody.

[object Object]

Sclerostin-binding antibody

Growing community of inventors

Berkshire, United Kingdom

Martyn Kim Robinson